Results 271 to 280 of about 100,300 (318)
Some of the next articles are maybe not open access.
Annual Review of Medicine, 2004
Advances in catheter and stent design have made stent implantation the standard coronary angioplasty procedure. Unfortunately, in-stent restenosis continues to plague this procedure, with the optimum binary restenosis rates reaching ∼10% to 20%. In the past few years, it has become clear that in-stent restenosis is largely due to the migration and ...
Porto I, Banning AP
openaire +5 more sources
Advances in catheter and stent design have made stent implantation the standard coronary angioplasty procedure. Unfortunately, in-stent restenosis continues to plague this procedure, with the optimum binary restenosis rates reaching ∼10% to 20%. In the past few years, it has become clear that in-stent restenosis is largely due to the migration and ...
Porto I, Banning AP
openaire +5 more sources
Stents and Drug-Eluting Stents
Otolaryngologic Clinics of North America, 2009Synechiae and ostial stenosis are common and troublesome complications following endoscopic sinus surgery. Many investigators have advocated the use of stents to minimize the risk of postoperative stenosis while others have found their use to be of no benefit. This article reviews the advantages and disadvantages of various stents used in sinus surgery,
Karen A, Bednarski, Frederick A, Kuhn
openaire +2 more sources
An Update on Drug-Eluting Stents
Current Treatment Options in Cardiovascular Medicine, 2012Coronary artery disease remains one of the major causes of morbidity and mortality worldwide. Percutaneous coronary intervention has been shown to be an effective treatment for angina pectoris, although it does not provide any prognostic benefit in stable patients.
Garg, Scot, Serruys, PWJC (Patrick)
openaire +3 more sources
In-stent Restenosis of drug-eluting Stents
Future Cardiology, 2013Drug-eluting stents (DES) have emerged as an improved alternative to bare-metal stents by demonstrating reduced rates of restenosis and target lesion revascularization. This emergence has led to the unrestricted use of DES for various indications and lesions, and subsequently revealed DES in-stent restenosis as a novel interventional therapeutic ...
Sa'ar, Minha +2 more
openaire +2 more sources
WIREs Nanomedicine and Nanobiotechnology, 2009
AbstractThis paper reviews the development of coronary stents from a polymer scientist's view point, and presents the first results of an interdisciplinary team assembled for the development of new stent systems. Poly(styrene‐b‐isobutylene‐b‐styrene) block copolymer (SIBS), a nanostructured thermoplastic elastomer, is used in clinical practice as the ...
Judit E, Puskas +8 more
openaire +2 more sources
AbstractThis paper reviews the development of coronary stents from a polymer scientist's view point, and presents the first results of an interdisciplinary team assembled for the development of new stent systems. Poly(styrene‐b‐isobutylene‐b‐styrene) block copolymer (SIBS), a nanostructured thermoplastic elastomer, is used in clinical practice as the ...
Judit E, Puskas +8 more
openaire +2 more sources
Drug-eluting stents: a critique
Heart, 2008Despite advances in the design of balloons and stents, restenosis remains a major drawback of coronary angioplasty. Multiple randomised trials have demonstrated that drug-eluting stents (DES) can significantly reduce rates of restenosis by 60–75% across both lesion and patient subsets.
N, Melikian, W, Wijns
openaire +2 more sources
Polymers for Drug Eluting Stents
Current Pharmaceutical Design, 2010Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue.
Ted, Parker +2 more
openaire +2 more sources
Nature Clinical Practice Cardiovascular Medicine, 2008
Drug-eluting stents (DESs) effectively reduce angiographic restenosis and the clinical need for repeat revascularization procedures as compared with bare-metal stents. Widely publicized concerns arose recently about the incidence of late and very late stent thrombosis with the use of first-generation DESs.
Stephan, Windecker, Peter, Jüni
openaire +2 more sources
Drug-eluting stents (DESs) effectively reduce angiographic restenosis and the clinical need for repeat revascularization procedures as compared with bare-metal stents. Widely publicized concerns arose recently about the incidence of late and very late stent thrombosis with the use of first-generation DESs.
Stephan, Windecker, Peter, Jüni
openaire +2 more sources
Mathematical Medicine and Biology, 2010
In this study, we consider a family of mathematical models to describe the elution of drug from polymer-coated stents into the arterial wall. Our models include the polymer layer, the media, the adventitia, a possible topcoat polymer layer and atherosclerotic plaque.
McGinty, Sean +3 more
openaire +3 more sources
In this study, we consider a family of mathematical models to describe the elution of drug from polymer-coated stents into the arterial wall. Our models include the polymer layer, the media, the adventitia, a possible topcoat polymer layer and atherosclerotic plaque.
McGinty, Sean +3 more
openaire +3 more sources
Drug-Eluting Stents in the Elderly
Current Treatment Options in Cardiovascular Medicine, 2010The introduction of drug-eluting stents (DES) in 2003 has had a great impact on the management of coronary artery disease in the United States. The application of DES to older adults, the population with the highest prevalence of and worst prognosis for coronary artery disease, remains relatively more controversial.
Samip, Vasaiwala +2 more
openaire +2 more sources